Funding
Funding not disclosed
Founders
Product
Problem
Research on sporadic amyotrophic lateral sclerosis (ALS) is limited by fragmented data sources and a lack of scalable tools to extract comprehensive phenotypic insights, slowing drug discovery and therapeutic development.
Solution
Cureforge International offers an AI-driven platform that performs deep phenotyping of sporadic ALS using publicly available datasets. The system integrates with existing research pipelines, providing complementary analytical outputs that enhance current experimental workflows. By applying advanced machine‑learning models, the platform identifies novel disease signatures and potential therapeutic targets, accelerating hypothesis generation and validation. Future extensions will incorporate agentic AI systems and digital twin simulations to broaden applicability across additional complex diseases.
Target Audience
Primary users are academic laboratories, biotech companies, and pharmaceutical research teams focused on ALS and other neurodegenerative disease drug discovery.
Features
- Deep phenotyping engine that aggregates and analyzes open‑source ALS datasets to generate high‑resolution disease profiles
- API and workflow connectors designed for seamless integration with standard bioinformatics and drug discovery tools
- Machine‑learning models that highlight novel biomarkers and candidate therapeutic pathways
- Scalable cloud infrastructure enabling rapid processing of large heterogeneous data collections
- Roadmap for agentic AI modules and digital twin simulations to model disease progression and treatment response